Xtant Medical Holdings (NYSE:XTNT) announced on April 13, 2026, that it has secured exclusive U.S. distribution rights for HEMOBLAST Bellows, a specialized hemostatic powder developed by Dilon Technologies.
Kymera Therapeutics (NASDAQ:KYMR) received U.S. Food and Drug Administration Fast Track designation for its experimental treatment for moderate-to-severe eosinophilic asthma, a move that could accelerate the path to market for the first-in-class oral therapy.
Aeluma (NASDAQ:ALMU), a pioneer in the development of high-performance optoelectronic devices, announced on April 13, 2026, that it has been awarded more than $4 million in new U.S. government contracts.
Perella Weinberg Partners (NASDAQ:PWP) has entered into a definitive agreement to acquire Gleacher Shacklock, a prominent London-based independent advisory firm.
Lazard (NYSE:LAZ) reported preliminary assets under management (AUM) of approximately $259.2 billion as of March 31, 2026.
Eli Lilly and Company (NYSE:LLY) announced Monday that its Phase 3 BRUIN CLL-322 trial achieved its primary endpoint, demonstrating that the addition of Jaypirca (pirtobrutinib) to a standard regimen of venetoclax and rituximab significantly extended the time patients lived without their disease worsening.
Somnigroup International (NYSE:SGI) reached an agreement to acquire Leggett & Platt (NYSE:LEG) in an all-stock transaction valued at approximately $2.5 billion, a move that unites the world's largest bedding brand owner with its primary component supplier.
Fastenal (NASDAQ:FAST), a global leader in the wholesale distribution of industrial and construction supplies, reported its financial results for the first quarter ended March 31, 2026, today.
Vertiv Holdings (NYSE:VRT), a global provider of critical digital infrastructure and continuity solutions, announced on April 13, 2026, the acquisition of BMarko Structures.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Telix Pharmaceuticals (NASDAQ:TLX) announced a landmark strategic collaboration on April 13, 2026, to co-develop and co-commercialize next-generation radiopharmaceutical therapies (RPTs).
Hillman Solutions (NASDAQ:HLMN), a leading provider of hardware products and merchandising solutions, announced on April 13, 2026, the acquisition of Delaney Hardware.
Allogene Therapeutics (NASDAQ:ALLO), a pioneer in allogeneic "off-the-shelf" CAR-T cell therapy, announced promising interim futility results today from its randomized Phase 2 ALPHA3 trial.
-640x360.webp&w=3840&q=75)
